What is the recommended treatment and follow‑up for a patient with confirmed monkeypox?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 29, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Mpox (monkeypox) confirmed: treatment and follow‑up

Bold recommendation: Treat most confirmed mpox cases with home isolation and supportive care; reserve tecovirimat for severe disease, high‑risk patients (e.g., immunocompromised, pregnant), or progressive/complicated lesions, and ensure strict follow‑up until lesions fully re‑epithelialize. 1, 2

1) Immediate infection control (reduces mortality and transmission)

  • Isolate at home until ALL lesions have crusted, scabs have fallen off, and fresh skin has formed (usually 2–4 weeks). Use dedicated bathroom if possible. Cover lesions; wear a mask during close contact; avoid sex and close skin contact. Disinfect high‑touch surfaces; do not share linens/clothing. 1, 2
  • Identify and notify close contacts for post‑exposure vaccination when available (JYNNEOS preferred over ACAM2000 due to safety). 1, 2

2) Who gets antivirals (prioritize morbidity, mortality, QOL)

Start oral tecovirimat now if ANY of the following:

  • Immunocompromised (e.g., advanced HIV, chemotherapy, high‑dose steroids), pregnant, children <8 years, severe dermatologic disease (e.g., atopic dermatitis), or extensive mucosal/genital/anorectal/oropharyngeal disease impacting function (pain, dysphagia, urinary retention). 1, 2
  • Severe/progressive disease (necrosis, hemorrhagic lesions), complications (encephalitis, pneumonia, sepsis), or hospitalization required. 1
  • If tecovirimat unavailable/contraindicated and severe disease: consider cidofovir/brincidofovir in consultation with ID specialists; monitor for nephrotoxicity/hepatotoxicity. Evidence is weaker than for tecovirimat. 1, 2

Nuance/strength:

  • Supportive care is standard for mild cases; no FDA‑approved mpox‑specific drug, but tecovirimat is widely used off‑label based on orthopox activity and clinical experience, including rapid resolution in severe immunocompromise. Highest‑quality recent data are limited; case series/case reports show benefit, especially in HIV with low CD4. 1, 3

3) How to give treatment

  • Supportive care for all:
    • Pain control: NSAIDs/acetaminophen; topical lidocaine for mucosal pain; stool softeners/sitz baths for anorectal lesions; saltwater gargles for oropharyngeal lesions. 1
    • Hydration and nutrition; treat secondary bacterial superinfection with targeted antibiotics only if purulence/cellulitis. Avoid routine corticosteroids. 1
  • Tecovirimat (TPOXX) typical regimen: 600 mg PO every 12 h for 14 days with a high‑fat meal; adjust for weight in pediatrics; consider IV if unable to take PO. Monitor for headache, nausea; drug–drug interactions are minimal. 1, 3
  • Alternatives (severe only, if TPOXX unavailable): cidofovir IV with probenecid and saline; brincidofovir PO where accessible. Balance potential benefits vs toxicities. 1

4) Special populations (prioritize severe outcome prevention)

  • Advanced HIV or low CD4: start tecovirimat promptly; resume/initiate ART; monitor closely for complications. Case data show rapid lesion resolution with tecovirimat. 3, 1
  • Pregnancy: prioritize tecovirimat to reduce maternal/fetal risk; avoid ACAM2000 vaccine if PEP considered; prefer non‑replicating JYNNEOS if vaccination needed. 1, 2
  • Children and eczema: lower threshold for antivirals and in‑person review due to risk of severe disease. 1

5) Follow‑up schedule and red flags

  • Follow‑up (telehealth acceptable): 48–72 h after diagnosis; then weekly until fully re‑epithelialized. Document pain control, new lesions, oral/rectal symptoms, hydration, secondary infection signs. 1
  • In‑person/ED immediately if any: altered mental status/seizure, respiratory distress/chest pain, severe dehydration, uncontrolled pain, rapidly progressive lesions/necrosis, extensive ocular involvement (urgent ophthalmology), urinary retention, inability to swallow. Admit for IV support/antivirals as needed. 1
  • For anorectal disease with severe pain or tenesmus, early tecovirimat and aggressive analgesia prevent morbidity and QOL decline. 1

6) Vaccination and contacts

  • Exposed close contacts: offer post‑exposure prophylaxis with JYNNEOS ASAP (ideally within 4 days, up to 14 days to reduce severity). Prefer JYNNEOS over ACAM2000 (fewer adverse events; safer in pregnancy/immunocompromise). 1, 2
  • ACAM2000 cautions: avoid in pregnancy, eczema, and immunocompromise due to risk of serious vaccine adverse events; these cautions derive from smallpox vaccine experience. 4

7) Common pitfalls to avoid

  • Delaying antivirals in high‑risk or function‑limiting mucosal disease—start tecovirimat early to prevent complications. 1
  • Inadequate pain control leading to dehydration, urinary retention, or malnutrition—treat pain proactively. 1
  • Using ACAM2000 in contraindicated groups—prefer JYNNEOS. 4, 1
  • Stopping isolation before full re‑epithelialization—maintain until fresh skin forms to cut transmission. 1, 2

References

1
Research

The 2022 human monkeypox outbreak: Clinical review and management guidance.

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2023

Related Questions

What is the recommended diagnostic approach, isolation precautions, and treatment—including antiviral therapy and post‑exposure vaccination—for a patient with suspected monkeypox (Mpox)?
What is the recommended treatment for monkeypox infection, including first‑line antiviral therapy and supportive care?
What is the recommended treatment for smallpox, including antiviral therapy, supportive care, and post‑exposure vaccination?
In a patient with a visually significant cataract and a persistently small pupil that does not adequately dilate, is combined phacoemulsification (phaco) and iridoplasty indicated?
What type of anemia does a 74‑year‑old polymorbid woman with hemoglobin 122 g/L, hematocrit 0.37, MCV 91.4 fL, MCH 30.1 pg, RDW 15 %, serum iron 13.4 µmol/L, transferrin 3.08 g/L, transferrin saturation 17.3 %, ferritin 39.9 µg/L, and CRP 4.41 mg/L have?
What is the recommended dosing and infusion schedule for meropenem administered as an extended (prolonged) infusion, including adjustments for infection severity and renal impairment?
What is the recommended pancreatic lipase dosing for infants (in international units per kilogram per feeding or meal)?
What are the causes of subchorionic hemorrhage?
Is a 4.3 cm aortic root in a patient without Marfan syndrome dangerous and does it warrant further investigation?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.